Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Abingdon, Oxfordshire
SEC filing record 1 source field available
Fiscal year end
31 December
Adaptimmune Therapeutics PLC has filed 808 SEC EDGAR filings since 02 Oct 2014

SEC filing history

Showing 551-575 of 808 matching filings.

Per page
25
Current page
23
4

FORM 4 SUBMISSION

Filing date
28 Mar 2018
Reporting date
26 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
28 Mar 2018
Reporting date
26 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
28 Mar 2018
Reporting date
26 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
28 Mar 2018
Reporting date
26 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
28 Mar 2018
Reporting date
26 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
21 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
21 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
21 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
21 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
21 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
21 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
21 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
21 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
21 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
23 Mar 2018
Reporting date
21 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
22 Mar 2018
Reporting date
20 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-37368

8-K

Filing date
15 Mar 2018
Reporting date
15 Mar 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88833

ADAPTIMMUNE THERAPEUTICS PLC

Filing date
14 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88833

SC 13G/A

Filing date
14 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88833

SC 13G/A filing

Filing date
13 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88833

SC 13G/A

Filing date
02 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88833

SC 13G/A

Filing date
02 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88833

SC 13G/A

Filing date
02 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88833

NEA 14 / ADAPTIMMUNE THERAPEUTICS PLC - 13GA (AMEND. #2)

Filing date
29 Jan 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .